Appointment booking for Dr. Subramanian Sivarajan, MD is currently not available.Dr. Subramanian Sivarajan, MD has not yet fully activated their profile on DiabetesIQ.
Dr. Subramanian Sivarajan, MD (he/him) is a Nephrologist in Palo Alto, CA with over 19 years of experience. What is your opinion of Dr. Subramanian Sivarajan, MD? Rate this provider below so other people can make informed decision.
Gender
Male
Experience
Over 19 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Subramanian Sivarajan, MD has received over $5,507 which includes payments from the following companies:
$2,416.55 from Keryx Biopharmaceuticals, Inc.
$672.48 from Alexion Pharmaceuticals, Inc.
$646.59 from Relypsa, Inc.
$545.67 from AstraZeneca Pharmaceuticals LP
$285.21 from Bard Peripheral Vascular, Inc.
$188.49 from Otsuka America Pharmaceutical, Inc.
$179.71 from Mallinckrodt LLC
$176.39 from Amgen Inc.
$135.16 from Fresenius USA Marketing, Inc.
$78.44 from Questcor Pharmaceuticals
$70.70 from sanofi-aventis U.S. LLC
$36.91 from Novartis Pharmaceuticals Corporation
$33.22 from Takeda Pharmaceuticals America, Inc.
$16.18 from NxStage Medical, Inc.
$14.65 from Genentech USA, Inc.
$11.23 from AMAG Pharmaceuticals, Inc.
Payments received by Dr. Subramanian Sivarajan, MD were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!